This inventor holds 7 USPTO granted patents and 1 published patent application and 2 EPO patents. Top assignees: Max-Planck-Gesellschaft Zur Förderung Der Wissenschaften E. V. , Aeterna Zentaris Gmbh, Other. Active years: 2001-2014.
Location History:
- Tübingen, DE (2001)
- La Jolla, CA (US) (2003 - 2012)
- Berlin, DE (2006 - 2014)
Company Filing History:
5 out of 1,327 
1 out of 36 
1 out of 834,307 Years Active: 2001-2014
Title: Thomas Rudel: Innovator in Cancer Therapy
Introduction
Thomas Rudel is a prominent inventor based in Berlin, Germany. He has made significant contributions to the field of cancer therapy through his innovative research and development. With a total of 7 patents, Rudel's work focuses on cytotoxic polypeptides and pharmaceutical compositions aimed at treating hyperproliferative disorders.
Latest Patents
Rudel's latest patents include a cytotoxic polypeptide that is an L-amino acid oxidase isolated from the ink of the sea hare. This invention serves as a target for cancer therapy. Additionally, he has developed pharmaceutical compositions that comprise inhibitors of Prohibitin (PHB) for the prevention and treatment of hyperproliferative disorders.
Career Highlights
Throughout his career, Thomas Rudel has worked with esteemed organizations, including the Max Planck Society for the Advancement of Science. His research has been pivotal in advancing therapeutic options for cancer patients.
Collaborations
Rudel has collaborated with notable individuals in his field, including Thomas F. Meyer and Daniel Butzke. These partnerships have further enhanced the impact of his research and innovations.
Conclusion
Thomas Rudel's contributions to cancer therapy through his patents and collaborations highlight his role as a key innovator in the field. His work continues to inspire advancements in medical research and treatment options.